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This article reviews current knowledge of the mechanisms underlying the initial hemorrhage and secondary blood–brain
barrier (BBB) dysfunction in primary spontaneous intracerebral hemorrhage (ICH) in adults. Multiple etiologies are
associated with ICH, for example, hypertension, Alzheimer’s disease, vascular malformations and coagulopathies
(genetic or drug-induced). After the initial bleed, there can be continued bleeding over the first 24 hours, so-called
hematoma expansion, which is associated with adverse outcomes. A number of clinical trials are focused on trying to
limit such expansion. Significant progress has been made on the causes of BBB dysfunction after ICH at the molecular
and cell signaling level. Blood components (e.g. thrombin, hemoglobin, iron) and the inflammatory response to those
components play a large role in ICH-induced BBB dysfunction. There are current clinical trials of minimally invasive
hematoma removal and iron chelation which may limit such dysfunction. Understanding the mechanisms underlying
the initial hemorrhage and secondary BBB dysfunction in ICH is vital for developing methods to prevent and treat this
devastating form of stroke.
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Each year, there are approximately 800,000 strokes in
the USA alone. Although ischemic stroke is the predom-
inant form, approximately 10-15% of these strokes are
intracerebral hemorrhage (ICH) and ICH accounts for
an even greater percentage of strokes in Asians [1]. ICH
is associated with a higher morbidity and mortality com-
pared to ischemic stroke [1]. The occurrence of ICH is
also a major concern in the prevention and treatment of
ischemia. Thus, anticoagulant treatment for prevention
of ischemia (brain and heart) is a growing cause of ICH
[2] and the occurrence of symptomatic ICH is a major
concern in using tissue plasminogen activator for trea-
ting ischemic stroke [3].
Although there are a number of ongoing clinical trials
[4], there is currently no FDA approved treatment for
ICH. Thus, understanding the mechanisms of brain in-
jury after ICH is important. Vascular disruption is the* Correspondence: rkeep@umich.edu
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unless otherwise stated.initial cause of ICH and blood–brain barrier (BBB) dys-
function (with associated edema and leukocyte extra-
vasation) is a secondary consequence [5]. It is vital to
understand the mechanisms underlying these two events
in ICH.
The aim of this article is to review current knowledge
about the mechanisms that may underlie the initial
hemorrhage and the secondary BBB dysfunction in adult
primary spontaneous ICH. With regards to the latter,
there is evidence that cerebral ischemia is not an impor-
tant component of brain injury after ICH in animal
models and in man [5]. Thus, while there is some over-
lap, there are distinct differences in the mechanisms
underlying BBB dysfunction between ischemic stroke
and ICH.
During this review, the term BBB dysfunction is used
to describe changes in BBB function post-ICH because
some of those changes can have deleterious effects (e.g.
brain edema may result in brain herniation and death).
However, it should be noted that the changes in function
may also be adaptive (e.g. infiltrating macrophages may
be involved in hematoma resolution). Whether the BBB
effects are detrimental or beneficial may depend ond. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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having adverse effects with large bleeds.
ICH Etiology and hematoma expansion
Hypertension is the most common cause of spontaneous
ICH, accounting for about two thirds of hemorrhages.
ICH is also linked to amyloid angiopathy, brain tumors
and various vascular malformations (e.g. aneurysms,
ateriovenous malformations, cerebral cavernous malfor-
mations) [7] (Table 1). Increasingly, anticoagulants are
also a cause. Their use now accounts for almost 20% of
ICH cases in the USA [2]. Location has important im-
pact on the frequency and outcome of ICH. Most ICH is
ganglionic or lobar [7] and hindbrain hemorrhages have
a worse outcome.
While most bleeding occurs at ictus, in about 30% of
ICH patients there is further bleeding (hematoma expan-
sion) during the course of the first day as shown by
brain imaging [7,8]. Such hematoma expansion is asso-
ciated with poor prognosis and it may, therefore, repre-
sent a therapeutic target [8].
Secondary BBB dysfunction
Brain injury and death may result from the initial
hemorrhage because of increased intracranial pressure,
brain herniation and physical disruption to the brain.
However, as in ischemic stroke, ICH also induces sec-
ondary brain damage [5]. This includes BBB dysfunction
as shown by evidence in animals and humans.
In animals, ICH has mostly been modeled by injecting
blood directly into the brain or by intracerebral injection
of collagenase. The latter causes bleeding (vascular dis-
ruption) via basement membrane degradation. After in-
tracerebral injection of blood into brain, there is delayedTable 1 Major causes of intracerebral hemorrhage
Etiology Proposed mechanism underlying
hemorrhage
Hypertension Vascular remodeling, formation
microaneurysms.
Amyloid angiopathy β-amyloid induced vascular damage.
Ateriovenous malformations Weakened vascular wall.
Cerebral cavernous malformations Weakened vascular wall.
Anti-coagulant usage Loss of coagulation in response
to bleeding (microbleeds).
Ischemic stroke* Ischemia/reperfusion induced
vascular injury
Traumatic brain injury* Physical disruption of vessels
Tumors* Abnormal vasculature
*In addition to primary spontaneous ICH, a hemorrhage can also be secondary
to other adverse events including an ischemic stroke (hemorrhagic
transformation), brain tumors and traumatic brain injury. Such hemorrhages
can have an important role in brain injury following such events. In ischemic
stroke, the risk of a symptomatic ICH is enhanced by inducing reperfusion
with tissue plasminogen activator (tPA).BBB hyperpermeability (Figure 1). In rat, Yang et al.
found no disruption at 4 hours but progressive disrup-
tion from 12 to 48 hours [9]. In pig, Wagner et al. found
no disruption from 1 to 8 hours, but found disruption
by 24 hours [10,11]. Following collagenase injection,
there was vascular disruption (bleeding) by 30 minutes,
but a prolonged lower level BBB hyperpermeability from
5 hours to 7 days [12]. In these animal models, hyper-
permeability is associated with brain edema formation
and an influx of inflammatory cells into the brain.
In human ICH, both acute and delayed vascular dis-
ruption occurs. As noted above, in some patients there
is continued bleeding and the extravasation of contrast
agent during the first 24 hours after ictus [8,13], but
there is also more delayed disruption [14,15] which may
be similar to that found after blood injection in animal
models. As in animal models, human BBB disruption
after ICH is associated with edema formation (Figure 2)
and an influx of leukocytes into brain [5,7].
It is difficult to assess the importance of secondary BBB
disruption in ICH. It will contribute to brain edema for-
mation (vasogenic edema), it may participate in neuroin-
flammation by facilitating leukocyte migration into brain,
and it will allow the entry of potentially harmful molecules
into brain (e.g. prothrombin which is converted to throm-
bin and may participate in brain injury; see below). How-
ever, while there are experimental treatments that reduce
BBB disruption and ameliorate ICH-induced brain injury,
those treatments are not ‘BBB-specific’ and it may be that
the beneficial effects come from parenchymal cells.
Mechanisms underlying initial hemorrhage
Hypertension
In hypertension, the cause of ICH is thought to relate to
remodeling of the cerebral vasculature. Thus, hyper-
tension can cause microaneurysms at the bifurcation of
arterioles and chronic elevation of intraluminal arterial
pressure can cause small vessel wall damage [16,17]. Inte-
restingly, in an animal model of ICH, salt fed stroke-prone
spontaneously hypertensive rats, BBB hyperpermeability
precedes hemorrhaging [18] suggesting there is a gradual
weakening of vascular integrity that eventually leads to
rupture. There is a genetic component to ICH [19]. Jeanne
et al. [20] identified rare mutations in collagen type IV, a
component of cerebrovascular basement membranes, that
were associated with ICH. Recently, Woo et al. [21], iden-
tified 1q22 as a susceptibility locus for non-lobar ICH,
although the precise gene involved is still uncertain. Lobar
ICH is often due to cerebral amyloid angiopathy and that
is discussed below.
Aneurysms
Cerebral aneurysms are balloon-like structures caused
by a weakness in a blood vessel wall. It has been
Figure 1 Photomicrographs showing both sides of serial coronal sections (thickness approximately 5 mm) containing hematoma (#)
and edematous white matter (*) 24 hours after blood infusion in a pig brain frozen in situ. Perihematomal edema is present as blue-staining
translucent regions in white matter adjacent to the hematoma. Evans blue staining is observed throughout the ipsilateral white matter and is indicative
of increased BBB permeability and vasogenic edema development. Figure/legend reprinted with permission from Journal of Neurosurgery [11].
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over 30 years old [22]. They are prone to rupture. Because
of location, bleeding is usually into the subarachnoid space
(causing subarachnoid hemorrhage; SAH), but ICH can
occur [23]. The risk of bleeding is low in previously
unruptured aneurysms, but aneurysm rupture accounts
for about 27,000 SAH cases per year in the USA [23].
Cavernous malformations
Cerebral cavernous malformations (CCMs) are mulberry-
shaped vascular lesions that occur in the capillary-venous
vascular bed [24]. They form vascular channels with little
or no intervening parenchymal tissue (Figure 3). The
growth (size and number) and bleeding of these lesions
can result in neurological symptoms. CCMs are generally
sporadic but some are familial (~20%) and, in the latter,loss-of-function mutations have been identified in three
genes: CCM1 (KRIT1), CCM2 (malcavernin, OSM,
MGC4607) and CCM3 (PDCD10) [24,25]. CCM1, 2 and 3
can form a complex (the CCM complex signaling platform
[25]) and regulate adhesion junction stability [24-26]. The
loss of this regulation through mutations may be involved
in both lesion growth and bleeding. It should be noted,
however, that there are differences in the cellular distri-
bution of CCM1, 2 and 3 [24,25] and they have important
actions outside the CCM complex [24,25]. Also, there is
evidence that CCMs regulate endothelial tight junction
function either directly or indirectly via altered adhesion
junction function [24]. While there is still much to be
learnt about the function of CCM proteins, they do have
important effects on endothelial junction proteins, and the
loss of those effects that may lead to bleeding.
Figure 2 Flair magnetic resonance imaging in a patient at day 1
after ICH. Note the marked edema (#) surrounding the hematoma (*).
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Ateriovenous malformations (AVMs) are a tangle of
blood vessels lacking a true capillary bed. These are
prone to rupture and cerebral hemorrhage is the most
severe AVM complication. A number of studies have ex-
amined genetic risk factors for hemorrhage. Polymor-
phisms in the EPHB4 gene encoding a tyrosine kinase
receptor involved in arterial-venous determination areFigure 3 Hematoxylin & eosin staining of a section from the
brain of a patient with cerebral cavernous malformation (type
CCM3). Note the multiple blood vessels with little or no intervening
parenchymal tissue. Scale bar = 200 μm.associated with bleeding in AVMs [27]. In addition, poly-
morphisms in the IL-6, TNFα , APOE (the APOEε2
allele) and IL-1β genes or gene promoters are associated
with hemorrhage in AVMs [28]. As described below, in-
flammation impacts cerebrovascular integrity.Amyloid angiopathy
Cerebral amyloid angiopathy (CAA) is the deposition of
β-amyloid in small arteries, arterioles and capillaries of the
cerebral cortex and leptomeninges [29-31]. β-amyloid is
thought to have damaging effects on the vasculature re-
sulting in microbleeds and symptomatic ICH, particularly
lobar ICH [31,32]. CAA occurs in almost all Alzheimer’s
disease patients, with severe CAA occurring in about 25%
of patients [31]. Patients with the APOEε2 or ε4 alleles are
at greater risk of ICH [31]. Polymorphism in the CR1
gene, encoding the complement component (3b/4b) re-
ceptor 1, is associated with development of Alzheimer’s
disease, likely because CR1 is involved in β-amyloid clea-
rance [33]. Recently, Biffi et al. found that a variant in the
CR1 gene was associated with increased risk of CAA-
related ICH [34].Infection
A recent study raises the interesting possibility that certain
types of infection may also cause ICH. Nakano et al. [35]
found that infection with a strain of Streptococcus mutans
(serotype k) expressing a collagen binding protein (CBP)
aggravated cerebral hemorrhage in mice and that the
incidence of S. mutans expressing the CBP was higher
in hemorrhagic stroke patients than control subjects.
Nakano et al. found that CBP-expressing S. mutans accu-
mulated in damaged vessels and that they inhibit collagen-
induced platelet activation. The impact of infections with
this strain of S. mutans in patients who are susceptible
to ICH (e.g. people with CCMs and AVMs) deserves
investigation.Anticoagulants
A growing proportion of ICH cases are linked to anti-
coagulant use, particularly the vitamin K antagonist
warfarin [1,2]. It has been estimated that there are about
2 million asymptomatic microhemorrhages a year in the
USA [36] and the presence of an anticoagulant may
transform a microbleed into a symptomatic ICH. The
presence of microbleeds increases the occurrence of
warfarin-associated ICH by more than 80-fold [37]. Re-
cently, a number of new orally active anticoagulants
have become available: dabigatran, a direct thrombin in-
hibitor, and rivaroxaban and apixaban, Factor Xa antago-
nists. Initial clinical trials suggest that these may induce
less ICH than warfarin [38].
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It should be noted that some patients with ischemic stroke
will undergo hemorrhagic transformation, i.e. hemorrha-
ging within the ischemic area [3,39]. Such hemorrhagic
transformation is a particular concern with tissue plas-
minogen activator (tPA)- induced reperfusion therapy for
ischemic stroke. It led to a number of failed clinical trials
of thrombolytics, with the adverse effect of increased
hemorrhage offsetting the benefit of reperfusion, before
the pivotal NINDS clinical trial [40] demonstrated a bene-
fit for tPA. Such hemorrhagic transformation is not the
focus of this review on primary spontaneous ICH. The
reader is referred to several excellent reviews on vascular
dysfunction in hemorrhagic transformation [3,39,41].
Mechanisms underlying hematoma expansion
That some patients continue to bleed (hematoma expan-
sion) after the initial ictus, suggests insufficient coa-
gulation. There have, therefore, been attempts to prevent
hematoma expansion by manipulating the coagulation cas-
cade. Notably, there was the trial of factor VIIa [42]. That
trial found a reduction in hematoma expansion but there
was no improvement in outcome. This may have been re-
lated to adverse side effects (particularly systemic) of factor
VIIa and the fact that only the 30% of patients that
undergo hematoma expansion would be expected to bene-
fit. There has, therefore, been interest in identifying which
patients are liable to undergo hematoma expansion (e.g.
those with the ‘spot sign’ on computerized tomography
angiography; [13]) and show most benefit from treatment.
Other techniques that might limit hematoma expansion
have been examined. Recently, there has been consider-
able interest on whether reducing blood pressure will limit
hematoma expansion (the INTERACT, ATACH and ICH
ADAPT clinical trials, [4,5]). The results of the phase 3
INTERACT2 trial were reported last year [43]. It showed
the apparent safety of acutely lowering blood pressure in
ICH patients and suggested a potential benefit on clinical
outcome, although this did not quite reach statistical
significance. Although the underlying rationale for this
(and other) blood pressure lowering trials was to lower
hematoma expansion, this phase 3 trial, in contrast to the
prior phase 2 trial, failed to show a significant effect of
blood pressure reduction on such expansion [43,44]. Even
earlier lowering of blood pressure may have a more bene-
ficial effect.
Mechanisms underlying secondary BBB dysfunction in ICH
The BBB is formed by the cerebral endothelial cells and
their linking tight junctions. The tightness of those junc-
tions and a relatively low level of transcytosis results in
the BBB having a very low permeability for many com-
pounds unless they are lipophilic or are subject to carrier-
mediated transport. In addition, under normal conditions,there is a very low rate of leukocyte migration into brain
across the cerebral endothelium. Perivascular cells (e.g.
pericytes and astrocytes) and endothelial-extracellular ma-
trix interactions also have a role in regulating BBB func-
tion, forming the so called neurovascular unit [45-49]. In
addition, leukocytes can also modulate BBB function upon
adhesion and during and after transmigration across the
endothelium [50].
An increase in BBB permeability and leukocyte infil-
tration into brain occurs in many neurological condi-
tions. Such an increase may occur via changes in the
paracellular (alterations in tight junction function) and/
or the transcellular route (transcytosis) across the cere-
bral endothelium [51]. However, while changes in the
para- and transcellular pathways across the endothelium
are the ultimate cause of increased permeability after
ICH, the effects of ICH may occur either directly on the
endothelium or indirectly via effects on other cell types
or extracellular matrix that regulate or affect the endo-
thelium. The purpose of this section is to outline what
ICH-factors may be involved in inducing BBB dysfunc-
tion (hyperpermeability and leukocyte transmigration),
the mechanisms involved and the potential impact on
ICH-induced brain injury.
ICH induces delayed BBB hyperpermeability [9-11]. A
potential cause could be ICH-induced ischemia, with the
hematoma mass increasing intracranial pressure and redu-
cing cerebral blood flow (a mass effect), as cerebral ische-
mia also increases BBB permeability [48]. However, the
role of ischemia in ICH-induced brain injury is controver-
sial [5,7]. Measurements in animal ICH models and a
number of human studies indicate that perihematomal
blood flows are not markedly reduced and do not reach
the levels required to induce ischemic brain damage
[52-54]. Indeed, reductions in blood flow may be a result
rather than the cause of brain damage (reduced tissue
oxygen demand and brain edema may reduce blood flow;
[52,54]). The apparent absence of ICH-induced ischemia
suggests that there are either components in blood that
increase permeability directly or that the response to those
components (e.g. inflammation) causes the hyperperme-
ability, and that the initiating causes of BBB dysfunction
differ from cerebral ischemia (Figure 4). It should be noted,
though, that there may be similarities in some of the down-
stream pathways activated to enhance BBB permeability
(e.g. inflammation and tight junction rearrangement).
Blood components and secondary blood–brain barrier
dysfunction in ICH
Thrombin
Thrombin is generated from plasma prothrombin after an
ICH for hemostasis. Intracerebral injection of thrombin
causes BBB disruption [55,56]. Many actions of thrombin
are mediated by protease activated receptors (PARs) and
Figure 4 The underlying cause of secondary BBB dysfunction
appears to differ in ICH (A) from cerebral ischemia (B). In ICH,
evidence indicates a major role for the presence of blood components
in brain parenchyma activating a number of pathways (cell injury,
receptor-mediated signaling and inflammation) leading to BBB
dysfunction. In contrast, in cerebral ischemia, the initiating cause
of injury is the lack of oxygen and glucose supply to the brain.
Delayed restoration of blood flow can also induce BBB dysfunction
(reperfusion injury). With ischemic injury, there are a number of
factors that can enhance the BBB dysfunction. Thus, for example,
hyperglycemia and tissue plasminogen activator (tPA) both can
result in hemorrhage after reperfusion. Less is known about factors
that enhance secondary BBB dysfunction in ICH.
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ruption by thrombin is at least partly PAR mediated
[56,58] and that thrombin phosphorylates Src kinases to
induce endothelial disruption [56]. A PAR-1 antagonist
blocked the BBB disruption induced by intraventricular
hemorrhage [59]. It should be noted, however, that intra-
cerebral thrombin induces an influx of leukocytes into
brain [60] and activates microglia [61] and, as discussed
below, inflammation may also cause BBB disruption.
Thus, thrombin may have both direct and indirect effects
on BBB function.
Fibrin
There may be other components in or derived from
plasma involved in BBB disruption and brain injury after
ICH. For example, after bleeding or BBB disruption, fi-
brinogen enters the brain and it is cleaved to form fibrin.
In multiple sclerosis, there is evidence that extravascular
fibrin is important in neuroinflammation and particularlymicroglia activation [62,63]. Although the role of fibrin/
fibrinogen in ICH-induced BBB disruption and brain in-
jury has not been studied, microglia activation has been
implicated in both (see below). The role of fibrin/fibrino-
gen and other plasma proteins in ICH deserves further
attention.
Erythrocyte components
Erythrocytes are another major component of intra-
cerebral hematomas and the role of erythrocytes and
erythrocyte components in ICH-induced injury has re-
ceived much attention [5,7,64]. Erythrocytes within the
intracerebral hematoma eventually lyse with hemoglobin
release and that hemoglobin can undergo degradation
leading to iron release [5,7,65] and intracerebral injec-
tion of lysed erythrocytes, hemoglobin and iron all cause
BBB disruption [66-69].
Although there may be other erythrocyte components
involved in ICH-induced brain injury [70], these results
suggest that the release and degradation of hemoglobin to
iron after erythrocyte lysis contributes to ICH-induced
BBB hyperpermeability. This hypothesis is supported by
data indicating reduced ICH-induced edema with ad-
ministration of an iron chelator, deferoxamine [71-73], or
a heme oxygenase (HO) inhibitor, zinc protoporphyrin
[74,75]. Heme oxygenases breakdown heme into biliver-
din, carbon monoxide, and iron [64]. Two isoforms of HO
are present in brain, the constitutive HO-2, and the indu-
cible HO-1 (including very marked induction by ICH
[76,77]). Interestingly, the effects of gene knockout (KO)
on ICH-induced brain injury differ for the two isoforms,
the HO-1 KO being protective while injury is greater in
the HO-2 KO, which may reflect the different cellular dis-
tribution of these isoforms [78,79]. It should also be noted,
though, that hemoglobin itself, as well as its degradation
products may be involved in inducing BBB dysfunction
[68]. There is also evidence that unconjugated bilirubin, a
metabolite of biliverdin, can also induce brain edema and
inflammation which may be linked to BBB effects [80].
It appears, therefore, that multiple factors produced
after erythrocyte lysis can affect BBB function, although
iron has a prominent role. Iron is generally thought to
cause BBB dysfunction by promoting the generation of
free radicals [81,82]. Oxygen and nitrogen free radicals
(e.g. superoxide, hydroxyl and peroxynitrite radicals) can
cause endothelial cell damage but also activate cell sig-
naling pathways that regulate BBB permeability [83,84].
Therapeutically, an iron chelator, deferoxamine, is now
in phase II clinical trial for ICH [85].
Inflammation and secondary BBB dysfunction in ICH
Blood components also induce an inflammatory response
in the perihematomal area. This includes perihematomal
leukocyte infiltration and microglia activation, as well as
Figure 5 During hematoma resolution after ICH, there is
phagocytosis of erythrocytes by invading macrophages/
microglia. Hematoxylin & eosin stained section from a pig ICH
model (described in [10]) at day 7 after blood injection. Note the
phagocytes engulfing erythrocytes (*) and the production of
hemosiderin, a breakdown product of hemoglobin (yellow staining).
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tion and activation of matrix metalloproteinases (MMPs)
[7,86-88]. There is evidence that each of these elements of
the inflammatory response can alter BBB function from
studies in ICH (see below) and other neurological condi-
tions [50]. In addition, changes in the BBB modulate the
inflammatory response. For example, the expression of
adhesion molecules on the cerebral endothelium is inte-
gral in leukocyte transmigration [50,89] and infiltrating
leukocytes are a major source of cytokines and MMPs
after ICH [90,91].
Neutrophils
In rodent models of ICH, neutrophils are the first leuko-
cytes to invade perihematomal brain tissue, with entry as
early as 4 hours and a peak at 48–72 hours [88,92,93].
Neutrophils are also found around hemorrhage and in
CSF after ICH in patients (reviewed in [88]). In animal
models, depleting neutrophils reduces ICH-induced
brain injury including secondary BBB disruption [90,94].
Similarly, toll-like receptor 4 is important in neutrophil
entry into brain after ICH and toll-like receptor 4 knock-
out mice have reduced neutrophil extravasation and
reduced ICH-induced brain injury [95]. The toll-like re-
ceptor 4-knockout mouse also has reduced macrophage
infiltration and microglia activation [96,97]. Neutrophils
are very important sources of TNFα [91] and matrix
metalloproteinase-9 (MMP-9) [90] after ICH and may,
thereby, influence the entry of other leukocytes into
brain and BBB disruption.
Monocytes
Monocytes also invade perihematomal brain tissue.
Thus, Hammond et al. [98] found marked invasion of
blood-derived monocytes at day 3 after ICH in the
mouse, with elevated levels still found at day 7. Two
populations of monocytes were detected, CCR2+Ly6Chi
and CX3CR1+Ly6C−. The former are inflammatory and
they peaked in brain before the latter which may have a
role in healing [98]. Depletion of inflammatory mono-
cytes reduced early ICH-induced brain injury. Injury was
also reduced in Ccr2-knockout mice and chimeric mice
with Ccr2−/− hematopoietic cells [98]. While monocytes
may have an adverse effect early in injury, they may also
have a role in tissue repair and hematoma phagocytosis
later after ICH [86,98,99] (see below; Figure 5).
Lymphocytes
The role of lymphocytes in ICH has received relatively lit-
tle attention. Xue and Del Bigio [93] noted an influx of
CD8a-immunoreactive lymphocytes into the brain be-
tween two and seven days after ICH. Peeling et al. [100]
found that the immunosuppressant FK-506 (tacrolimus)
reduced lymphocyte extravasation after ICH. Rolland et al.[101] found a similar effect with fingolimod, a sphingosine
1-phosphate receptor analog. Both FK-506 and fingolimod
also improved functional outcome, although it should be
noted that the effects of both drugs were not limited to re-
ducing lymphocyte infiltration into brain. Whether lym-
phocytes play a role in BBB dysfunction after ICH has not
been examined.
In cerebral ischemia and other neurological conditions
such as multiple sclerosis, there has been in depth in-
vestigation of the mechanisms involved in leukocyte trans-
migration into brain [50,102,103]. Transmigration is a
multiple step process in which adhesion molecules on
both cerebral endothelial cells and leukocytes play a cen-
tral role [50,102,103]. The mechanism by which neutro-
phils, macrophages and lymphocytes enter the brain after
ICH has received much less attention. Several studies have
shown an upregulation of intercellular adhesion molecule-
1 (ICAM-1) after experimental ICH [92,101,104] and
Rolland et al. found that fingolimod blocked both ICAM-1
upregulation and lymphocyte transmigration into brain
[101]. Loftspring et al. [80] found that unconjugated biliru-
bin could also induce ICAM-1 upregulation, suggesting a
role of this hemoglobin breakdown product in inflam-
mation after ICH. Ma et al. found upregulation of another
adhesion molecule, vascular adhesion protein-1 (VAP-1)
after experimental ICH [105] and VAP-1 inhibition had an
anti-inflammatory effect [105]. It is likely that multiple ad-
hesion molecules are involved in leukocyte infiltration into
brain after ICH.
Microglia
Microglia are rapidly activated after ICH. For example,
after intracerebral blood injection in the rat, activated
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lasted for at least 4 weeks [93]. A number of studies
have shown that acute inhibition of microglia reduces
ICH-induced brain injury [87,88] including BBB disrup-
tion [91,106]. It should be noted, however, that in ICH
(as in other neurological conditions), microglia can have
beneficial as well as detrimental effects [87,88], effects
which are time-dependent [87]. Thus, microglia are
involved in hematoma phagocytosis, tissue repair and can
have anti- as well as proinflammatory effects [87,88]. An
alternate therapeutic approach is to modify microglial
activation to promote the beneficial effects. Peroxisome
proliferator activated receptor (PPAR)-gamma agonists
promote the M2 (phagocytic) phenotype in microglia
rather than the proinflammatory M1 phenotype and
PPAR-gamma agonists have shown benefit in animal ICH
models [86,99]. Pioglitazone, a PPAR-gamma agonist, is
now in clinical trial for ICH [107].
Cytokines
Cytokines are signaling molecules that play a central role
in inflammatory processes. A variety of cytokines are
overexpressed in perihematomal tissue after ICH in
animals and man [108,109] and such changes are also
found at the protein level. For example, perihematomal
TNFα is markedly increased by 2–4 hours in rat ICH
[110] and Sun et al. found prolonged increases in peri-
hematomal IL-1β [111]. Some cytokines are known to
increase BBB permeability by activating signaling path-
ways within the endothelium and by indirect effects on
other cells of the neurovascular unit [48,112,113]. In
ICH, King et al. [114] found a TNFα receptor antagonist
could reduce ICH-induced BBB hyperpermeability.
Other studies have shown that curcumin [115], erythro-
poietin [116] and a combination of dexamethasone and
melatonin [117] decrease cytokine levels and reduce
BBB permeability after ICH.
Chemokines regulate chemotaxis, including the migra-
tion of leukocytes. Genomic studies have shown that a
range of chemokines are overexpressed in perihematomal
tissue after in animal and human ICH [108,109] and this
may relate to the leukocyte influx that occurs after
hemorrhage. Ma et al. found protein levels of monocyte
chemoattractant protein 1 (CCL2) were increased after ex-
perimental ICH [105]. Yao and Tsirka [118] investigated
the effects of genetic deletion of CCL2 and its receptor,
CCR2, on ICH-induced brain injury. They found that
CCL2 or CCR2 deletion reduced hematoma size in a
mouse collagenase ICH model, reduced early microglial
activation/migration but increased microglia numbers
later after ICH. The deletions also reduced leukocyte infil-
tration. Apart from regulating leukocyte migration and
microglial activation, CCL2 can also increase BBB perme-
ability by inducing the internalization of transmembranetight junction proteins [119-122]. These results suggest
that chemokines may play an important role in BBB dys-
function after ICH.
Matrix metalloproteinases
MMPs play a central role in neuroinflammatory processes
by degrading elements of the extracellular matrix. Intrace-
rebral injection of bacterial collagenase (a form of MMP)
causes hemorrhage [123] and a number of MMPs are
upregulated in animal ICH models (e.g. MMP-2, −3, −9
and −12 [124]). MMPs may come from different sources.
For example, astrocytes can produce MMP-2, microglia
can produce MMP-3 and −12, and neurons can produce
MMP-3, but infiltrating neutrophils are a major source of
MMP-9 [124], indeed the reduced brain and BBB injury
found with neutrophil depletion in rat ICH may be related
to reduced MMP-9 levels [90]. There is also evidence for
MMP upregulation in ICH patients in blood, CSF and
perihematomal tissue (reviewed in [125]). MMP-2 and −9
are upregulated in brains of patients with cerebral amyloid
angiopathy including in areas far from the acute ICH
[126,127]. There is, therefore, interest in the role of MMPs
in inducing ICH and in secondary brain injury, including
BBB disruption.
Although MMPs are best known for extracellular matrix
degradation, there is evidence of MMP-mediated cleavage
of the BBB tight junction proteins, occludin and claudin-5
[128-131]. Thus, MMPs may affect BBB function and
hemorrhage by multiple mechanisms, including disrup-
tion of the physical support by the endothelial basement
membrane, altered endothelial: extracellular matrix sig-
naling, promotion of leukocyte migration and direct ef-
fects on tight junction proteins.
The potential role of MMPs in ICH has been exa-
mined in patients by examining whether MMP expres-
sion correlates with outcome or markers of injury and
in animals by examining the effects of MMP inhibi-
tion or genetic deletion on ICH. Thus, several studies
have shown that MMP-9 expression correlates with
hematoma expansion, perihematomal edema and neu-
rological deterioration in ICH patients (reviewed in
[125]). Li et al. recently found that increased plasma
MMP-3 and MMP-9 levels were associated with worse
outcome in ICH patients but not in brain edema [132].
Animal MMP inhibition/genetic deletion studies in ICH
have given some conflicting results. Thus, the broad-
based MMP inhibitors GM6001 [133,134] and BB-1101
[135], and genetic deletion of MMP-12 [136] reduced
ICH-induced brain injury. In contrast, another MMP
inhibitor, BB-94, increased ICH-induced injury [137], as
did genetic deletion of MMP-9 [138]. These diver-
gent effects of MMP manipulation may reflect the
diverse roles of different MMPs, roles which may vary
with time.
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There are currently a number of clinical trials for ICH
therapy (Table 2). As blood components may have dele-
terious effects on the brain (neurons, glia as well as the
BBB), and because the presence of the hematoma may
cause physical disruption and increase intracranial pres-
sure, there have been many trials of clot evacuation in
ICH (see [139] for a meta-analysis). As yet, these trials
have not shown a definitive benefit for surgical removal,
including the recent STICH2 trial [140]. This might re-
flect some of the adverse side effects of surgery. There
are currently a number of clinical trials using minimally
invasive surgery in combination with clot lysis. An
example is the current phase III Minimally Invasive Sur-
gery plus rtPA for Intracerebral Hemorrhage Evacuation
(MISTIE) trial which uses t-PA to aid in clot removal
[141]. This has recently been reported to reduce perihe-
matomal edema which may suggest reduced BBB per-
meability [142].
A potential concern of such trials is that surgery or
surgery plus tPA might cause the release of factors from
the hematoma (e.g. hemoglobin and iron) that are detri-
mental to the brain parenchyma and the brain vascula-
ture. It is possible that the iron chelator, deferoxamine,
which is now in phase II clinical trial for ICH [85], might
be of benefit as an adjunct therapy for such clot removal
approaches.Table 2 Current and recently (2010 and later) finished clinica
Intervention Study name Clinical tria
Surgical Evacuation STICH II
Surgical Evacuation/tPA MISTIE III NCT018270
Blood pressure lowering agents ATACH-II NCT011765
Blood pressure lowering agents INTERACT2 NCT007160
Blood pressure lowering agents ICH-ADAPT NCT009639
Factor VIIa (for spot sign patients) SPOTLIGHT NCT013592
Factor VIIa (for spot sign patients) STOP IT NCT008108
Factor VIIa (reversal anticoagulants) NCT007707
Platelet Transfusion NCT006996
Pioglitazone SHRINC NCT008278
Deferoxamine iDEF NCT021752
Minocycline MACH NCT018058
Simvastatin NCT007183
Fluoxetine NCT017375
Albumin NCT009905
Hypothermia NCT018663
Ibuprofen NCT015308
Details on clinical trials can be found from the NIH (http://www.clinicaltrials.gov) an
#For older clinical trials, the reader is referred to Keep et al. [5].
*The effect of acute blood pressure lowering did not quite reach statistical significaAs noted above, there are a number of clinical trials
focused on acutely reducing blood pressure to limit
hematoma expansion [4]. Another pharmacological ap-
proach to affect hematoma size is to promote clot
resolution. Microglia/macrophages are involved in clot
phagocytosis and this is stimulated by PPAR-gamma ago-
nists, such as pioglitazone [86,99]. It should be noted that
PPAR-gamma agonists may have other beneficial effects
(anti-inflammatory and anti-oxidant) in ICH. There is a
current trial (SHRINC) of pioglitazone in ICH [107].Conclusion
Intracerebral hemorrhage has a variety of etiologies and
the mechanisms causing the initial hemorrhage and sub-
sequent BBB disruption may differ with etiology. Thera-
peutic approaches may also need to differ (e.g. between
hypertensive ICH and that following amyloid angio-
pathy). However, since our last short review on BBB
function in ICH [143], there has been progress made
in understanding the mechanisms that underlie initial
hemorrhage and secondary BBB dysfunction at the mo-
lecular, cellular and tissue level. There are a number of
promising current clinical trials for ICH [4] that may
limit those processes. Hopefully, the first successful
treatments for this devastating form of stroke are not
too long in the future.l trials for treating ICH#
l # Target Outcome
Multiple No benefit [140]
46 Multiple Ongoing
65 Hematoma expansion Ongoing
79 Hematoma expansion Inconclusive*[43]
76 Hematoma expansion Ongoing
02 Hematoma expansion Ongoing
88 Hematoma expansion Ongoing
18 Hematoma expansion Terminated (poor recruitment)
21 Hematoma expansion Ongoing
92 Hematoma resolution Ongoing
25 Iron toxicity Ongoing
95 Inflammation Ongoing
28 Multiple Terminated (poor recruitment)
41 Motor recovery Ongoing
09 Multiple Terminated (PI move)
84 Multiple Ongoing
80 Fever prevention Ongoing
d The Internet Stroke Center (http://www.strokecenter.org/trials/).
nce in the phase 3 INTERACT2 trial.
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